Nevro Corp. is expected to pay $20 million to Boston Scientific Corp. after a Delaware jury found that the medical device company had infringed on two Boston Scientific patents related to the manufacturing of a spinal cord stimulation technology, the company said late Monday.
The jury found that Nevro infringed on two lead patents involving the ways spinal cord stimulation technology were manufactured. The manufacturing methods were implemented by a third-party supplier, Nevro
NVRO,
said. Two other Boston Scientific
BSX,
patents weren’t infringed.
“We disagree with the finding by the jury and plan to appeal,” Nevro General Counsel Kashif Rashid said in a release.
The jury’s decision doesn’t have any commercial implications or place any restrictions on current or future Nevro products, the Redwood City, Calif., company said. The amount of money that will be awarded to Boston Scientific won’t have a material effect on its business, Nevro said.
“We are gratified that the jury upheld Boston Scientific spinal cord stimulation lead patents and recognized that Nevro should pay for infringing those patents,” a Boston Scientific spokeswoman said in an emailed statement.
This post was originally published on Market Watch
